Hepatic Complications of Obesity

Gastroenterology Clinics of North America

Volumn 39, Issue 1, 2010, Pages 57-68

  Diehl, Anna Mae ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cirrhosis; Hepatocellular carcinoma; Nonalcoholic fatty liver disease; Steatohepatitis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; BETAINE; BILE SALT; CANNABINOID 1 RECEPTOR ANTAGONIST; CASPASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; LIPOPROTEIN; LOSARTAN; METFORMIN; PIOGLITAZONE; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; RESVERATROL; ROSIGLITAZONE; TROGLITAZONE; URSODEOXYCHOLIC ACID;

BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG FATALITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIVER BIOPSY; LIVER CANCER; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; METABOLIC DISORDER; MOLECULAR MECHANICS; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; POSITIVE END EXPIRATORY PRESSURE; PROGNOSIS; PSYCHOPATHY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

BARIATRIC SURGERY; BIOPSY, NEEDLE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FATTY LIVER; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; OBESITY; OBESITY, MORBID; PROGNOSIS; THIAZOLIDINEDIONES; TRANSAMINASES; WEIGHT LOSS;

EID: 77349119425     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2009.12.001     Document Type: Review

References (90)

1. Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr Rev 65 6 Pt 2 (2007) S57-S63
2. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 6 (2004) 1387-1395
3. Bingham A., Mamyrova G., Rother K.I., et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 87 2 (2008) 70-86
4. Dam-Larsen S., Becker U., Franzmann M.B., et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol 44 10 (2009) 1236-1243
5. Choi S.S., and Diehl A.M. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol 19 3 (2008) 295-300
6. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 6 (1999) 1413-1419
7. Yeh M.M., and Brunt E.M. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 128 5 (2007) 837-847
8. Bellentani S., Saccoccio G., Masutti F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132 2 (2000) 112-117
9. McCullough A.J. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 8 3 (2004) 521-533 viii
10. Teli M.R., James O.F., Burt A.D., et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22 6 (1995) 1714-1719
11. Feldstein A.E., Papouchado B.G., Angulo P., et al. Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 3 4 (2005) 384-389
12. Richardson M.M., Jonsson J.R., Powell E.E., et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 133 1 (2007) 80-90
13. Gramlich T., Kleiner D.E., McCullough A.J., et al. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 35 2 (2004) 196-199
14. Jou J., Choi S.S., and Diehl A.M. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 28 4 (2008) 370-379
15. Lefkowitch J.H. Morphology of alcoholic liver disease. Clin Liver Dis 9 1 (2005) 37-53
16. Adams L.A., Sanderson S., Lindor K.D., et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42 1 (2005) 132-138
17. Hashizume H., Sato K., Takagi H., et al. Primary liver cancers with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 19 10 (2007) 827-834
18. Siegel A.B., and Zhu A.X. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 115 24 (2009) 5651-5661
19. Ratziu V., Giral P., Charlotte F., et al. Liver fibrosis in overweight patients. Gastroenterology 118 6 (2000) 1117-1123
20. Vega G.L., Chandalia M., Szczepaniak L.S., et al. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology 46 3 (2007) 716-722
21. Bellentani S., and Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 8 Suppl 1 (2009) S4-S8
22. Adams L.A., Lindor K.D., and Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 99 7 (2004) 1316-1320
23. Fargion S., Mattioli M., Fracanzani A.L., et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 96 8 (2001) 2448-2455
24. Yoneda M., Nozaki Y., Endo H., et al. Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. Dig Dis Sci (2009) [Epub ahead of print]
25. Ma X., Holalkere N.S., Kambadakone R.A., et al. Imaging-based quantification of hepatic fat: methods and clinical applications. Radiographics 29 5 (2009) 1253-1277
26. Mofrad P., Contos M.J., Haque M., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37 6 (2003) 1286-1292
27. Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18-the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther 30 11-12 (2009) 1103-1109
28. Ratziu V., Giral P., Munteanu M., et al. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther 25 2 (2007) 207-218
29. Wieckowska A., McCullough A.J., and Feldstein A.E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 46 2 (2007) 582-589
30. Wieckowska A., and Feldstein A.E. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 28 4 (2008) 386-395
31. Angulo P. Noninvasive assessment of fibrosis and steatosis in NASH and ASH. Gastroenterol Clin Biol 33 10-11 (2009) 940-948
32. Arun J., Jhala N., Lazenby A.J., et al. Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass. Obes Surg 17 2 (2007) 155-161
33. Ratziu V., Charlotte F., Heurtier A., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 7 (2005) 1898-1906
34. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 8 (2001) 1844-1850
35. Gholam P.M., Flancbaum L., Machan J.T., et al. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 102 2 (2007) 399-408
36. Mishra P., Nugent C., Afendy A., et al. Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int 28 8 (2008) 1080-1086
37. Liangpunsakul S., and Chalasani N. Is hypothyroidism a risk factor for non-alcoholic steatohepatitis?. J Clin Gastroenterol 37 4 (2003) 340-343
38. Hassan M.M., Kaseb A., Li D., et al. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 49 5 (2009) 1563-1570
39. Kamada Y., Takehara T., and Hayashi N. Adipocytokines and liver disease. J Gastroenterol 43 11 (2008) 811-822
40. Denzer C., Thiere D., Muche R., et al. Gender-specific prevalences of fatty liver in obese children and adolescents: roles of body fat distribution, sex steroids, and insulin resistance. J Clin Endocrinol Metab 94 10 (2009) 3872-3881
41. Suzuki A., and Abdelmalek M.F. Nonalcoholic fatty liver disease in women. Womens Health (Lond Engl) 5 2 (2009) 191-203
42. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 1 (2005) 113-121
43. Adams L.A., and Lindor K.D. Nonalcoholic fatty liver disease. Ann Epidemiol 17 11 (2007) 863-869
44. Erickson S.K. Nonalcoholic fatty liver disease. J Lipid Res 50 Suppl (2009) S412-S416
45. Sanyal A.J., Banas C., Sargeant C., et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43 4 (2006) 682-689
46. Ratziu V., Bonyhay L., Di Martino V., et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35 6 (2002) 1485-1493
47. Burke A., and Lucey M.R. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 4 5 (2004) 686-693
48. Cortez-Pinto H., and Machado M. Impact of body weight, diet and lifestyle on nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2 2 (2008) 217-231
49. Leclercq I.A., and Horsmans Y. Nonalcoholic fatty liver disease: the potential role of nutritional management. Curr Opin Clin Nutr Metab Care 11 6 (2008) 766-773
50. Caldwell S., and Lazo M. Is exercise an effective treatment for NASH? Knowns and unknowns. Ann Hepatol 8 Suppl 1 (2009) S60-S66
51. Harrison S.A., Fecht W., Brunt E.M., et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49 1 (2009) 80-86
52. Kral J.G., and Naslund E. Surgical treatment of obesity. Nat Clin Pract Endocrinol Metab 3 8 (2007) 574-583
53. Hansen E.N., Torquati A., and Abumrad N.N. Results of bariatric surgery. Annu Rev Nutr 26 (2006) 481-511
54. Mummadi R.R., Kasturi K.S., Chennareddygari S., et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 6 12 (2008) 1396-1402
55. Rafiq N., and Younossi Z.M. Effects of weight loss on nonalcoholic fatty liver disease. Semin Liver Dis 28 4 (2008) 427-433
56. Mathurin P., Hollebecque A., Arnalsteen L., et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137 2 (2009) 532-540
57. Trakhtenbroit M.A., Leichman J.G., Algahim M.F., et al. Body weight, insulin resistance, and serum adipokine levels 2 years after 2 types of bariatric surgery. Am J Med 122 5 (2009) 435-442
58. Vuppalanchi R., and Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 49 1 (2009) 306-317
59. Browning J.D. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 44 2 (2006) 466-471
60. Kiyici M., Gulten M., Gurel S., et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 17 12 (2003) 713-718
61. Hyogo H., Tazuma S., Arihiro K., et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 57 12 (2008) 1711-1718
62. Laurin J., Lindor K.D., Crippin J.S., et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23 6 (1996) 1464-1467
63. Yokohama S., Yoneda M., Haneda M., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40 5 (2004) 1222-1225
64. Lavine J.E. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 136 6 (2000) 734-738
65. Adams L.A., and Angulo P. Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy. Am J Gastroenterol 98 11 (2003) 2348-2350
66. Harrison S.A., Torgerson S., Hayashi P., et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98 11 (2003) 2485-2490
67. Yakaryilmaz F., Guliter S., Savas B., et al. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern Med J 37 4 (2007) 229-235
68. Abdelmalek M.F., Angulo P., Jorgensen R.A., et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 96 9 (2001) 2711-2717
69. Abdelmalek M.F., Sanderson S.O., Angulo P., et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 50 6 (2009) 1818-1826
70. Georgescu E.F., and Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 16 1 (2007) 39-46
71. Nair S., Diehl A.M., Wiseman M., et al. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 20 1 (2004) 23-28
72. Marchesini G., Brizi M., Bianchi G., et al. Metformin in non-alcoholic steatohepatitis. Lancet 358 9285 (2001) 893-894
73. Bugianesi E., Gentilcore E., Manini R., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100 5 (2005) 1082-1090
74. Lindor K.D., Kowdley K.V., Heathcote E.J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39 3 (2004) 770-778
75. Chamulitrat W., Burhenne J., Rehlen T., et al. Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent. Hepatology 50 1 (2009) 143-154
76. Dufour J.F., Oneta C.M., Gonvers J.J., et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 4 12 (2006) 1537-1543
77. Loguercio C., Federico A., Tuccillo C., et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 39 6 (2005) 540-543
78. Lirussi F., Mastropasqua E., Orando S., et al. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 1 (2007) CD005165
79. Flier J.S., and Maekalanos J.J.A. Gut check: testing a role for the intestinal microbiome in human obesity. Sci Transl Med 1 6 (2009) 1-3
80. Witek R.P., Stone W.C., Karaca F.G., et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 50 5 (2009) 1421-1430
81. Feldstein A.E., Canbay A., Angulo P., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125 2 (2003) 437-443
82. Mallat A., and Lotersztajn S. Cannabinoid receptors as therapeutic targets in the management of liver diseases. Drug News Perspect 21 7 (2008) 363-368
83. Chaudhary N., and Pfluger P.T. Metabolic benefits from Sirt1 and Sirt1 activators. Curr Opin Clin Nutr Metab Care 12 4 (2009) 431-437
84. Marchesini G., Brizi M., Morselli-Labate A.M., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107 5 (1999) 450-455
85. Caldwell S.H., Hespenheide E.E., Redick J.A., et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96 2 (2001) 519-525
86. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38 4 (2003) 1008-1017
87. Sanyal A.J., Mofrad P.S., Contos M.J., et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2 12 (2004) 1107-1115
88. Ratziu V., Giral P., Jacqueminet S., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135 1 (2008) 100-110
89. Ratziu V., Charlotte F., Bernhardt C., et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology (2009) [Epub ahead of print]
90. Yki-Jarvinen H. Thiazolidinediones and the liver in humans. Curr Opin Lipidol 20 6 (2009) 477-483